In this age of rapidly evolving technologies that fundamentally shift the way businesses operate, such as large language models (LLMs) and natural language processing (NLP), organizations are quickly realizing that success extends beyond innovative technology solutions alone. While these technologies offer immense potential in terms of innovation, data insights and operational efficiency gains, constraints exist… The post Navigating the intersection of technology and human expertise in life sciences appeared first on Drug Discovery and Development ..read more

In early 2022, secretive Altos Labs stunned with a record $3 billion launch to pursue anti-aging “cellular rejuvenation,” amid rumors of Jeff Bezos’ backing. But a roundup of the top 25 private healthcare and biotech companies reveals a landscape of grand ambitions to disrupt healthcare coupled with cautionary tales. Included in the mix is scandal-plagued… The post Top 25 best-funded private healthcare and biotechnology companies: From Altos to Theranos and beyond appeared first on Drug Discovery and Development ..read more

The same week that BenevolentAI announced it was cutting 30% of its staff, AI-focused biotech Xaira Therapeutics debuted with a $1 billion funding round with little precedent in healthcare over the past year — or beyond that. A survey of the biggest fundraising rounds over the past year revealed that the absolute largest investments were… The post Xaira’s $1 billion launch one of the biggest recent biotech funding rounds appeared first on Drug Discovery and Development ..read more

Cell and gene therapies are upending the treatment of a growing number of diseases by addressing the underlying causes of genetic disorders. Yet the high costs associated with these therapies, sometimes costing multiple millions of dollars for a single treatment, pose significant challenges for patients, payers and healthcare systems. To address this matter, a growing… The post From Novartis to Pfizer: A closer look at novel cell and gene therapy pricing and reimbursement strategies appeared first on Drug Discovery and Development ..read more

Yes, generative AI is hyped. And yes, the technology has shortcomings. But the landscape is swiftly changing. Bloomberg Intelligence estimated that the GenAI market would grow from $40 billion in 2022 to $1.3 trillion by 2032. A recent study from Deloitte Consulting estimates that for a top 10 biopharma company with $65-75 billion in revenue,… The post The $5-7B generative AI opportunity biopharma can’t afford to ignore appeared first on Drug Discovery and Development ..read more

The recent emergence of H5N1 avian influenza in humans and animals has intensified global efforts to prepare for a potential pandemic. Public health agencies and international organizations are collaborating with pharmaceutical companies and academic institutions to develop vaccines, treatments, and strategies to mitigate the impact of an outbreak. The CDC, for instance, has released interim… The post Public vs. private: Who’s leading the charge in H5N1 preparedness? appeared first on Drug Discovery and Development ..read more

The FDA has signed off on two novel therapies targeting rare pediatric cancers. Novartis’ Lutathera targets aggressive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in children 12 and up, while Day One Biopharma’s Ojemda (tovorafenib) tackles treatment-resistant BRAF-mutated relapsed or refractory pediatric low-grade glioma (pLGG) with a BRAF fusion or rearrangement, or BRAF V600 mutation These approvals offer… The post FDA approves pair of therapies for rare pediatric cancers: Novartis’ Lutathera and Day One’s Ojemda appeared first on Drug Discovery and Development ..read more

Endometriosis, a condition where endometrial tissue grows outside the uterus, has a strong genetic underpinning. A new study published in the Journal of Molecular Diagnostics sheds light on this connection. Researchers from a team including Genzeva, LumaGene, RYLTI Biopharma, Brigham & Women’s Hospital of Harvard University and QIAGEN Digital Insights used a unique approach in… The post Study combines biomimetic AI, digital twins and multiomics to unveil potential genetic drivers of endometriosis appeared first on Drug Discovery and Development ..read more

Pulmonary arterial hypertension (PAH), a rare, progressive and life-threatening blood vessel disorder, affects some 500 to 1,000 new patients each year in the U.S. FDA recently approved Opsynvi, a first-of-its-kind once-daily single-tablet combination therapy from Johnson & Johnson. “With this approval, our portfolio now includes treatments that address all three guideline-recommended pathways,” said a J&J… The post How the FDA approval of J&J’s Opsynvi could simplify treatment and improve outcomes for PAH patients appeared first on Drug Discovery and Development ..read more

Medincell and AbbVie today announced a collaboration to co-develop and commercialize up to six therapeutic products across several areas. The partnership spans multiple therapeutic spaces and indications. Under the agreement, Medincell will use its commercial-stage, long-acting injectable technology platform to formulate innovative therapies. It plans to conduct formulation activities and preclinical studies, including supportive CMC… The post Medincell, AbbVie partner on long-term injectable therapies appeared first on Drug Discovery and Development ..read more